New drug aimed at reversing fatty liver disease shows promise in trial
Disease control
Terminated
This study tests a drug called Aramchol in people with nonalcoholic steatohepatitis (NASH), a serious liver condition linked to obesity and diabetes. The goal is to see if Aramchol can reduce liver scarring and improve liver health. About 150 adults with confirmed NASH and modera…
Phase: PHASE3 • Sponsor: Galmed Research and Development, Ltd. • Aim: Disease control
Last updated May 26, 2026 12:04 UTC